Published in Arterioscler Thromb Vasc Biol on November 11, 2010
Crizanlizumab for the Prevention of Pain Crises in Sickle Cell Disease. N Engl J Med (2016) 2.62
Platelets as cellular effectors of inflammation in vascular diseases. Circ Res (2013) 2.62
NF-κB is activated in CD4+ iNKT cells by sickle cell disease and mediates rapid induction of adenosine A2A receptors. PLoS One (2013) 1.50
Interplay between coagulation and vascular inflammation in sickle cell disease. Br J Haematol (2013) 1.12
Regulation of neutrophil function by adenosine. Arterioscler Thromb Vasc Biol (2012) 1.11
Targeting iNKT cells for the treatment of sickle cell disease. Clin Immunol (2011) 1.09
Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood (2013) 1.07
Regulation of leukocyte function by adenosine receptors. Adv Pharmacol (2011) 1.04
Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology. Blood (2016) 0.96
Blood cells and endothelial barrier function. Tissue Barriers (2015) 0.94
Tissue factor promotes activation of coagulation and inflammation in a mouse model of sickle cell disease. Blood (2012) 0.93
The LSD1 inhibitor RN-1 induces fetal hemoglobin synthesis and reduces disease pathology in sickle cell mice. Blood (2015) 0.89
Synergistic Action of Staphylococcus aureus α-Toxin on Platelets and Myeloid Lineage Cells Contributes to Lethal Sepsis. Cell Host Microbe (2015) 0.87
Platelet abnormalities during colonic inflammation. Inflamm Bowel Dis (2013) 0.87
Intravital imaging of mesenchymal stem cell trafficking and association with platelets and neutrophils. Stem Cells (2015) 0.87
Platelet activation and platelet-leukocyte aggregation elicited in experimental colitis are mediated by interleukin-6. Inflamm Bowel Dis (2014) 0.83
Endothelial activation by platelets from sickle cell anemia patients. PLoS One (2014) 0.83
Staphylococcus aureus α-hemolysin promotes platelet-neutrophil aggregate formation. J Infect Dis (2013) 0.82
Platelet-neutrophil interactions under thromboinflammatory conditions. Cell Mol Life Sci (2015) 0.82
Prominent role of platelets in the formation of circulating neutrophil-red cell heterocellular aggregates in sickle cell anemia. Haematologica (2014) 0.82
Lung vaso-occlusion in sickle cell disease mediated by arteriolar neutrophil-platelet microemboli. JCI Insight (2017) 0.80
Hydroxyurea with AKT2 inhibition decreases vaso-occlusive events in sickle cell disease mice. Blood (2015) 0.80
Immune parameter analysis of children with sickle cell disease on hydroxycarbamide or chronic transfusion therapy. Br J Haematol (2015) 0.80
Tissue factor and thrombin in sickle cell anemia. Thromb Res (2012) 0.78
Glycoprotein Ibα inhibitor (CCP-224) prevents neutrophil-platelet aggregation in Sickle Cell Disease. Blood Adv (2017) 0.75
Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science (1997) 4.25
Complete reversal of acid-induced acute lung injury by blocking of platelet-neutrophil aggregation. J Clin Invest (2006) 3.38
Sickle blood contains tissue factor-positive microparticles derived from endothelial cells and monocytes. Blood (2003) 3.04
Thrombogenesis in sickle cell disease. J Lab Clin Med (2001) 2.75
Primary role for adherent leukocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci U S A (2002) 2.72
Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest (2000) 2.47
Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease. Blood (2005) 2.37
Expression, activation, and function of integrin alphaMbeta2 (Mac-1) on neutrophil-derived microparticles. Blood (2008) 2.36
Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin. Blood (2007) 2.31
Platelets as immune cells: bridging inflammation and cardiovascular disease. Circ Res (2007) 2.22
Increased neutrophil-platelet adhesion in patients with unstable angina. Circulation (1996) 2.20
Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion. Blood (2000) 2.10
Platelet-neutrophil-interactions: linking hemostasis and inflammation. Blood Rev (2006) 2.08
Biologically active CD40 ligand is elevated in sickle cell anemia: potential role for platelet-mediated inflammation. Arterioscler Thromb Vasc Biol (2006) 2.06
Identification of critical antigen-specific mechanisms in the development of immune thrombocytopenic purpura in mice. Blood (2000) 1.90
Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood (1998) 1.79
Endothelial cell expression of tissue factor in sickle mice is augmented by hypoxia/reoxygenation and inhibited by lovastatin. Blood (2004) 1.73
NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines. Blood (2009) 1.69
Reperfusion injury pathophysiology in sickle transgenic mice. Blood (2000) 1.65
Flow cytometric detection of activated mouse integrin alphaIIbbeta3 with a novel monoclonal antibody. Cytometry (2002) 1.62
Hypercoagulability in sickle cell disease: a curious paradox. Am J Med (2003) 1.47
High expression of human beta S- and alpha-globins in transgenic mice: hemoglobin composition and hematological consequences. Proc Natl Acad Sci U S A (1992) 1.42
P-selectin mediates Ca(2+)-dependent adhesion of activated platelets to many different types of leukocytes: detection by flow cytometry. Blood (1992) 1.41
High expression of human beta S- and alpha-globins in transgenic mice: erythrocyte abnormalities, organ damage, and the effect of hypoxia. Proc Natl Acad Sci U S A (1992) 1.37
Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion. Blood (2007) 1.33
Platelet activation in patients with sickle cell disease. Br J Haematol (1998) 1.29
Platelet binding to monocytes increases the adhesive properties of monocytes by up-regulating the expression and functionality of beta1 and beta2 integrins. J Leukoc Biol (2006) 1.26
Platelets are essential for leukocyte recruitment in allergic inflammation. J Allergy Clin Immunol (2003) 1.26
Stimulation of P-selectin glycoprotein ligand-1 on mouse neutrophils activates beta 2-integrin mediated cell attachment to ICAM-1. Eur J Immunol (1998) 1.21
Neutrophil activation in sickle cell disease. J Leukoc Biol (1999) 1.19
Platelet, but not endothelial, P-selectin is critical for neutrophil-mediated acute postischemic renal failure. FASEB J (2001) 1.12
Platelet activation and interaction with leucocytes in patients with sepsis or multiple organ failure. Eur J Clin Invest (1995) 1.12
Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation. Thromb Haemost (2005) 1.11
Activated monocytes and platelet-monocyte aggregates in patients with sickle cell disease. Clin Lab Haematol (2002) 1.10
Circulating activated platelets assist THP-1 monocytoid/endothelial cell interaction under shear stress. Blood (1999) 1.10
Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia. J Lab Clin Med (1997) 1.09
Circulating platelet-neutrophil complexes represent a subpopulation of activated neutrophils primed for adhesion, phagocytosis and intracellular killing. Br J Haematol (1999) 1.07
Platelet-leukocyte interactions in inflammation and atherothrombosis. Semin Thromb Hemost (2007) 1.07
Sickle red cells induce adhesion of lymphocytes and monocytes to endothelium. Blood (2008) 1.05
Clopidogrel: a review of its mechanism of action. Platelets (1998) 1.05
Platelets, coagulation, and fibrinolysis in sickle cell disease: their possible role in vascular occlusion. Blood Coagul Fibrinolysis (1991) 1.03
Platelet and leucocyte activation in childhood sickle cell disease: association with nocturnal hypoxaemia. Br J Haematol (2000) 1.01
Platelet-monocyte complexes support monocyte adhesion to endothelium by enhancing secondary tethering and cluster formation. Arterioscler Thromb Vasc Biol (2003) 1.00
Adhesive interactions of sickle erythrocytes with endothelium. J Clin Invest (1997) 1.00
Fibronectin bridges monocytes and reticulocytes via integrin alpha4beta1. Br J Haematol (2008) 0.96
The role of leukocyte and endothelial adhesion molecules in ischemia-reperfusion injury. Thromb Haemost (1997) 0.96
Platelet-erythrocyte adhesion in sickle cell disease. J Investig Med (1999) 0.94
Inflammatory potential of neutrophils detected in sickle cell disease. Am J Hematol (2004) 0.94
The panoply of animal models for sickle cell anaemia. Br J Haematol (2001) 0.91
Morphological and functional platelet abnormalities in Berkeley sickle cell mice. Blood Cells Mol Dis (2008) 0.90
A double-blind trial of ticlopidine in sickle cell disease. Thromb Haemost (1984) 0.89
Contact-induced neutrophil activation by platelets in human cell suspensions and whole blood. Blood (1992) 0.89
Preliminary trial of minidose heparin prophylaxis for painful sickle cell crises. East Afr Med J (1989) 0.89
Trial of low doses of aspirin as prophylaxis in sickle cell disease. J Pediatr (1983) 0.88
Platelet P-selectin and platelet mass, volume and component in sickle cell disease: relationship to genotype. Thromb Res (2005) 0.87
Platelet activation during pain crisis in sickle cell anemia patients. Am J Hematol (1989) 0.87
Increased adhesive properties of eosinophils in sickle cell disease. Exp Hematol (2004) 0.84
Promising therapies in sickle cell disease. Cardiovasc Hematol Disord Drug Targets (2009) 0.84
Mechanisms of platelet-neutrophil interactions and effects on cell filtration in septic shock. Shock (2002) 0.83
Platelet activation during steady state sickle cell disease. J Med (1983) 0.83
Selectin blockade reduces neutrophil interaction with platelets at the site of deep arterial injury by angioplasty in pigs. Arterioscler Thromb Vasc Biol (1999) 0.80
Erythrocyte/endothelial interactions and the vasocclusive severity of sickle cell disease. Prog Clin Biol Res (1981) 0.79
Selectin on activated platelets enhances neutrophil endothelial adherence in myocardial reperfusion injury. Cardiovasc Res (1999) 0.77
Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med (2007) 10.00
Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov (2008) 4.76
International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and classification of adenosine receptors--an update. Pharmacol Rev (2011) 4.16
Elevated circulating fibrocyte levels in patients with hypertensive heart disease. J Hypertens (2012) 2.79
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2007) 2.69
Risk factors for hospital readmission within 30 days: a new quality measure for children with sickle cell disease. Pediatr Blood Cancer (2009) 2.66
Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation. J Exp Med (2006) 2.62
Cutting edge: Critical role for A2A adenosine receptors in the T cell-mediated regulation of colitis. J Immunol (2006) 2.37
A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. J Immunol (2005) 2.37
Compartmentalization of neutrophils in the kidney and lung following acute ischemic kidney injury. Kidney Int (2009) 2.30
Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages. Am J Physiol Renal Physiol (2004) 2.27
Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: the role of CD4+ T cells and IFN-gamma. J Immunol (2006) 2.22
Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest (2003) 2.22
Dendritic cells tolerized with adenosine A₂AR agonist attenuate acute kidney injury. J Clin Invest (2012) 2.00
2-Aminothiophene-3-carboxylates and carboxamides as adenosine A1 receptor allosteric enhancers. Bioorg Med Chem (2005) 1.94
Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation (2006) 1.94
Infarct-sparing effect of A2A-adenosine receptor activation is due primarily to its action on lymphocytes. Circulation (2005) 1.75
NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines. Blood (2009) 1.69
Activation of A2A adenosine receptor attenuates intestinal inflammation in animal models of inflammatory bowel disease. Gastroenterology (2005) 1.66
Therapeutic anti-inflammatory effects of myeloid cell adenosine receptor A2a stimulation in lipopolysaccharide-induced lung injury. J Immunol (2007) 1.62
Lipopolysaccharide rapidly modifies adenosine receptor transcripts in murine and human macrophages: role of NF-kappaB in A(2A) adenosine receptor induction. Biochem J (2005) 1.60
Extracellular adenosine regulates naive T cell development and peripheral maintenance. J Exp Med (2013) 1.57
Adenosine A2A receptors induced on iNKT and NK cells reduce pulmonary inflammation and injury in mice with sickle cell disease. Blood (2010) 1.56
Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: inhibition of chemokine induction. Am J Physiol Gastrointest Liver Physiol (2004) 1.55
Adenosine A2A receptor activation attenuates inflammation and injury in diabetic nephropathy. Am J Physiol Renal Physiol (2005) 1.52
NF-κB is activated in CD4+ iNKT cells by sickle cell disease and mediates rapid induction of adenosine A2A receptors. PLoS One (2013) 1.50
A2B adenosine receptor gene deletion attenuates murine colitis. Gastroenterology (2008) 1.49
Comparison of systemic and retrograde delivery of adenosine A2A agonist for attenuation of spinal cord injury after thoracic aortic cross-clamping. Ann Thorac Surg (2006) 1.44
Additive protection against lung ischemia-reperfusion injury by adenosine A2A receptor activation before procurement and during reperfusion. J Thorac Cardiovasc Surg (2007) 1.42
Pulmonary thrombi are not detected by 3D magnetic resonance angiography in adults with sickle cell anemia and an elevated triscuspid regurgitant jet velocity. Am J Hematol (2009) 1.42
The A2B adenosine receptor impairs the maturation and immunogenicity of dendritic cells. J Immunol (2009) 1.39
Human A(2A) adenosine receptors: high-affinity agonist binding to receptor-G protein complexes containing Gbeta(4). Mol Pharmacol (2002) 1.39
A novel neutrophil-specific PET imaging agent: cFLFLFK-PEG-64Cu. J Nucl Med (2009) 1.36
Activation of adenosine 2A receptors attenuates allograft rejection and alloantigen recognition. J Immunol (2007) 1.32
A2A adenosine receptor activation improves survival in mouse models of endotoxemia and sepsis. J Infect Dis (2004) 1.32
Adenosine A2A agonists in development for the treatment of inflammation. Expert Opin Investig Drugs (2005) 1.31
Anatomy of adenosine A2A receptors in brain: morphological substrates for integration of striatal function. Neurology (2003) 1.31
A2A adenosine receptors on bone marrow-derived cells protect liver from ischemia-reperfusion injury. J Immunol (2005) 1.30
CD4+ T lymphocytes mediate acute pulmonary ischemia-reperfusion injury. J Thorac Cardiovasc Surg (2009) 1.28
Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol (2011) 1.28
A critical role of the adenosine A2A receptor in extrastriatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum and forebrain A2A receptor knock-outs. J Neurosci (2008) 1.27
Complex inheritance pattern of dyskeratosis congenita in two families with 2 different mutations in the telomerase reverse transcriptase gene. Blood (2007) 1.26
CD73 is expressed by human regulatory T helper cells and suppresses proinflammatory cytokine production and Helicobacter felis-induced gastritis in mice. J Infect Dis (2009) 1.25
Adenosine A2A receptor antagonists exert motor and neuroprotective effects by distinct cellular mechanisms. Ann Neurol (2008) 1.24
Recurrent, severe wheezing is associated with morbidity and mortality in adults with sickle cell disease. Am J Hematol (2011) 1.24
Adenosine A2A receptor activation reduces inflammation and preserves pulmonary function in an in vivo model of lung transplantation. J Thorac Cardiovasc Surg (2005) 1.22
Adenosine A2A receptor activation on CD4+ T lymphocytes and neutrophils attenuates lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg (2009) 1.17
Inactivation of the adenosine A2A receptor protects apolipoprotein E-deficient mice from atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.14
The A2B adenosine receptor promotes Th17 differentiation via stimulation of dendritic cell IL-6. J Immunol (2011) 1.13
The role of adenosine A2A receptor signaling in bronchiolitis obliterans. Ann Thorac Surg (2009) 1.13
Purinergic regulation of epithelial transport. J Physiol (2003) 1.13
Adenosine signaling via the adenosine 2B receptor is involved in bronchiolitis obliterans development. J Heart Lung Transplant (2010) 1.12
Activation of adenosine 2A receptors preserves structure and function of podocytes. J Am Soc Nephrol (2007) 1.12
Activation of A2A adenosine receptors inhibits expression of alpha 4/beta 1 integrin (very late antigen-4) on stimulated human neutrophils. J Leukoc Biol (2003) 1.11
Epitope spreading and autoimmune glomerulonephritis in rats induced by a T cell epitope of Goodpasture's antigen. J Am Soc Nephrol (2005) 1.10
A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization. Neuropsychopharmacology (2005) 1.10
Leukocyte compartments in the mouse lung: distinguishing between marginated, interstitial, and alveolar cells in response to injury. J Immunol Methods (2011) 1.09
Targeting iNKT cells for the treatment of sickle cell disease. Clin Immunol (2011) 1.09
Reduction of infarct size and postischemic inflammation from ATL-146e, a highly selective adenosine A2A receptor agonist, in reperfused canine myocardium. Am J Physiol Heart Circ Physiol (2004) 1.08
Adenosine A₂A agonist improves lung function during ex vivo lung perfusion. Ann Thorac Surg (2011) 1.07
Sickle cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. Blood (2013) 1.07
Links between insulin resistance, adenosine A2B receptors, and inflammatory markers in mice and humans. Diabetes (2011) 1.06
An A2A adenosine receptor agonist, ATL313, reduces inflammation and improves survival in murine sepsis models. BMC Infect Dis (2008) 1.02
Adenosine A2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation. Am J Physiol Heart Circ Physiol (2008) 1.02
Activation of A1, A2A, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg (2010) 1.01
A1 adenosine receptor activation promotes angiogenesis and release of VEGF from monocytes. Circ Res (2007) 1.00
Adenosine A2B receptors are highly expressed on murine type II alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol (2009) 1.00
Optimization of a mouse locomotor rating system to evaluate compression-induced spinal cord injury: correlation of locomotor and morphological injury indices. J Neurosurg Spine (2006) 0.99
Methacholine challenge in children with sickle cell disease: a case series. Pediatr Pulmonol (2008) 0.99
Allosteric enhancers of A1 adenosine receptors increase receptor-G protein coupling and counteract Guanine nucleotide effects on agonist binding. Mol Pharmacol (2003) 0.96
Adenosine A2A receptor activation limits graft-versus-host disease after allogenic hematopoietic stem cell transplantation. J Leukoc Biol (2009) 0.96
Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function. Infect Immun (2005) 0.96
Rapid modification of the glycocalyx caused by ischemia-reperfusion is inhibited by adenosine A2A receptor activation. Am J Physiol Heart Circ Physiol (2003) 0.95
Structure-activity relationships at human and rat A2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem (2002) 0.95
2-Amino-3-aroyl-4,5-alkylthiophenes: agonist allosteric enhancers at human A(1) adenosine receptors. J Med Chem (2002) 0.94
Adenosine A2A receptor signaling and golf assembly show a specific requirement for the gamma7 subtype in the striatum. J Biol Chem (2010) 0.94
Limitations of clinical trials in sickle cell disease: a case study of the Multi-center Study of Hydroxyurea (MSH) trial and the Stroke Prevention (STOP) trial. Hematology Am Soc Hematol Educ Program (2007) 0.94
2-aminothienopyridazines as novel adenosine A1 receptor allosteric modulators and antagonists. J Med Chem (2008) 0.94
Inhibiting CXCL12 blocks fibrocyte migration and differentiation and attenuates bronchiolitis obliterans in a murine heterotopic tracheal transplant model. J Thorac Cardiovasc Surg (2012) 0.93
Adenosine-mediated cardioprotection in ischemic-reperfused mouse heart. J Cardiovasc Pharmacol (2002) 0.93
Multi-modal intervention and prospective implementation of standardized sickle cell pain admission orders reduces 30-day readmission rate. Pediatr Blood Cancer (2009) 0.92
Quinazolines as adenosine receptor antagonists: SAR and selectivity for A2B receptors. Bioorg Med Chem (2003) 0.92
Laparoscopic versus open abdominal surgery in children with sickle cell disease is associated with a shorter hospital stay. Pediatr Blood Cancer (2008) 0.92
Protection from pulmonary ischemia-reperfusion injury by adenosine A2A receptor activation. Respir Res (2009) 0.92
Adenosine A(2B) receptor deficiency promotes host defenses against gram-negative bacterial pneumonia. Am J Respir Crit Care Med (2012) 0.91
Enhanced fibrinolysis protects against lung ischemia-reperfusion injury. J Thorac Cardiovasc Surg (2009) 0.91
The evolution of ischemic spinal cord injury in function, cytoarchitecture, and inflammation and the effects of adenosine A2A receptor activation. J Thorac Cardiovasc Surg (2004) 0.89
Protein kinase A mediates inhibition of the thrombin-induced platelet shape change by nitric oxide. Blood (2004) 0.89